Stockreport

Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF On December 12, Morgan Stanley analyst Terence Flynn raised the firm's price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $768 from $767 and kept an Equal [Read more]